Johannes Oosthuizen - Nov 7, 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
President, U.S. Market
Signature
/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen
Stock symbol
MRK
Transactions as of
Nov 7, 2022
Transactions value $
-$4,531,980
Form type
4
Date filed
11/7/2022, 03:09 PM
Previous filing
Nov 1, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $0 +14.7K +129.61% $0.00 26K Nov 7, 2022 Direct
transaction MRK Common Stock Options Exercise $0 +17.5K +67.01% $0.00 43.5K Nov 7, 2022 Direct
transaction MRK Common Stock Options Exercise $0 +13.5K +31.13% $0.00 57K Nov 7, 2022 Direct
transaction MRK Common Stock Options Exercise $0 +7.05K +12.35% $0.00 64.1K Nov 7, 2022 Direct
transaction MRK Common Stock Sale -$4.53M -45.6K -71.09% $99.47 18.5K Nov 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -14.7K -100% $0.00* 0 Nov 7, 2022 Common Stock 14.7K $62.07 Direct F3
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -17.5K -100% $0.00* 0 Nov 7, 2022 Common Stock 17.5K $77.62 Direct F4
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -13.5K -66.66% $0.00 6.77K Nov 7, 2022 Common Stock 13.5K $75.36 Direct F5
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -7.05K -33.33% $0.00 14.1K Nov 7, 2022 Common Stock 7.05K $73.73 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2 Holdings include shares acquired in dividend reinvestment transactions.
F3 The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020.
F4 The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
F5 The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
F6 The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.